Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Two new studies from Associate Professor Simon Newstead in the Department of Biochemistry reveal how a family of membrane proteins that enable us to absorb protein in our food can transport thousands of different peptide fragment into cells.

Lipid Cubic Phase crystallisation of bacterial POT family transporters has revealed key insights into the peptide binding site
Lipid Cubic Phase crystallisation of bacterial POT family transporters has revealed key insights into the peptide binding site

The work of Professor Newstead and colleagues, which combines high-resolution structural studies and thermodynamics, reveals the tricks that the transporters use to accomplish this promiscuity (1,2). They show that a bacterial version of the transporter, PepT1, uses different mechanisms to accommodate and transport a diverse range of peptides. If the human peptide transporter also uses two mechanisms, then companies who are interested in exploiting the transporters’ ability to actively take up a number of clinically important drugs such as antibiotics and antivirals, could hone their strategy for targeting these transporters for drug uptake.

Read more (Department of Biochemistry website)

Similar stories

Five ways the pandemic has affected routine medical care

Since the beginning of the pandemic, COVID has infected at least a third of the UK population and is estimated to have factored in the deaths of almost 200,000 people in the UK. But critically, COVID has also had a devastating impact on our healthcare systems. While this was expected, new evidence is beginning to reveal the scope of the issue – in particular the effects for people living with long-term health conditions.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Mechanism of expanding bacteria revealed

A new study published in Nature has identified a potential Achilles heel in the protective layers surrounding Gram-negative bacteria that could aid in the development of next-generation antibiotics.

Discovery of gene involved in chronic pain creates new treatment target

Oxford researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord, helping them to understand an important mechanism underlying chronic pain in humans and providing a new treatment target.

Oxford's largest ever study into Varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications establishes for the first time, a critical genetic risk score to predict the likelihood of patients suffering with Varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Biological processes of ageing is key to improving later life health

Improvements in health care, sanitation, and diet over last 100 years have significantly increased life expectancy. However, this increase in how long we can expect to live has not been accompanied by a similar increase in healthy life expectancy, defined as the time spent free of major illness or disease.